Pathologist MD, PhD | University of Bari Aldo Moro | Italy
Eliano Cascardi, MD, PhD, is a distinguished pathologist specializing in precision and regenerative medicine. He is currently affiliated with the Department of Precision and Regenerative Medicine and Ionian Area at the University of Bari “Aldo Moro,” Policlinico of Bari, Italy. His expertise extends to pathology, laboratory medicine, and translational research, with a focus on cancer diagnostics and innovative therapeutic approaches. Dr. Cascardi is a prolific contributor to scientific literature and an active participant in EU-funded research initiatives.
Profile
Scopus
Education
Dr. Cascardi has an impressive educational background. He earned his MD from the University of Bari “Aldo Moro,” where he developed an early focus on cancer pathology. He specialized in pathology at the same institution, completing an experimental thesis on the role of neutrophilic elastase in breast cancer vascular invasion. Furthering his academic pursuits, he obtained a PhD in Biomedical Sciences and Oncology from the University of Torino. Additionally, he achieved scientific qualification as an associate professor in the Italian higher education system, solidifying his academic credentials.
Experience
Dr. Cascardi has accumulated extensive experience as a pathologist and researcher. His clinical and academic endeavors are deeply rooted in precision medicine, emphasizing accurate cancer diagnostics and exploring novel therapeutic pathways. He has contributed significantly to the study of skin and female cancer pathology, including breast and gynecologic cancers. Beyond clinical practice, Dr. Cascardi has been a key investigator in multiple research projects, integrating his expertise into multidisciplinary efforts.
Research Interests
Dr. Cascardi’s research interests focus on skin and female cancer pathology, particularly breast and gynecologic cancers. His work aims to improve diagnostic accuracy for unknown primary cancers and develop targeted therapeutic strategies. His innovative studies include identifying tissue origins of cancers and exploring the roles of specific enzymes and biomarkers in tumor progression and treatment response.
Awards and Nominations
Dr. Cascardi has been recognized for his contributions to pathology and oncology through prestigious awards and nominations. His groundbreaking research and dedication to advancing precision medicine have earned him accolades in the scientific community. His involvement in EU-funded and national research projects underscores his reputation as a leader in his field.
Selected Publications
Dellino, M. et al. (2024). “Artificial Intelligence in Cervical Cancer Screening: Opportunities and Challenges.” AI, 5(4), 2984–3000. [Cited by 10 articles].
Cazzato, G., Cascardi, E., et al. (2024). “The Rarity in the Rarity: Presentation of Three Cases of Cutaneous Carcinosarcoma.” Dermatopathology, 11(3), 209. [Cited by 7 articles].
Cascardi, E., et al. (2024). “Oral–Gut–Estrobolome Axis May Exert a Selective Impact on Oral Cancer.” Journal of Dental Research. [Cited by 5 articles].
Forte, M., Cascardi, E., et al. (2024). “Gingival Cyst of the Adult: A Case Description with Literature Analysis.” Reports, 7(3), 51. [Cited by 2 articles].
Sallicandro, L., Cascardi, E., et al. (2024). “Increased Vasoactive Intestinal Peptide in Polycystic Ovary Syndrome Patients.” Frontiers in Endocrinology, 15. [Cited by 3 articles].
Dellino, M., Cascardi, E., et al. (2023). “The Strange Case of Twin Reversed Arterial Perfusion (TRAP) Sequence.” Diagnostics, 13, 3109. [Cited by 8 articles].
Cazzato, G., Cascardi, E., et al. (2023). “Cutaneous Metastasis from Internal Malignancies: The Revealing Role of the Skin.” Cancers, 15(17), 4351. [Cited by 6 articles].
Conclusion
Dr. Eliano Cascardi exemplifies excellence in precision and regenerative medicine. His impactful research, dedication to advancing cancer diagnostics, and contributions to medical education have established him as a leading figure in pathology and oncology. Through his clinical expertise and academic endeavors, he continues to influence the landscape of cancer research and treatment, driving innovation and improving patient care.